1. Cell Cycle/DNA Damage
    Cytoskeleton
    Apoptosis
    Metabolic Enzyme/Protease
  2. Microtubule/Tubulin
    Apoptosis
    Endogenous Metabolite
  3. Docetaxel

Docetaxel  (Synonyms: RP-56976)

Cat. No.: HY-B0011 Purity: 99.96%
COA Handling Instructions

Docétaxel (RP-56976) est un agent antinéoplasique et inhibe la dépolymérisation des microtubules avec une valeur IC50 de 0,2 μM. Docétaxel (RP-56976) atténue les effets de l'expression des gènes bcl-2 et bcl-xL. Docétaxel (RP-56976) arrête le cycle cellulaire à G2/M et conduit à l'apoptose cellulaire.

Docetaxel (RP-56976) ist ein antineoplastisches Mittel und hemmt die microtubule depolymerization mit einem IC50-Wert von 0,2 μM. Docetaxel (RP-56976) schwächt die Auswirkungen der bcl-2 and bcl-xL-Genexpression ab. Docetaxel (RP-56976) hemmt den Zellzyklus bei G2/M und führt zur apoptosis.

Docetaxel (RP-56976) is a microtubule depolymerization inhibitor, with an IC50 of 0.2 μM. Docetaxel attenuates the effects of bcl-2 and bcl-xL gene expression. Docetaxel arrests the cell cycle at G2/M and leads to cell apoptosis. Docetaxel has anti-cancer activity.

For research use only. We do not sell to patients.

Docetaxel Chemical Structure

Docetaxel Chemical Structure

CAS No. : 114977-28-5

Size Price Stock Quantity
Free Sample (0.1 - 0.5 mg)   Apply Now  
Solution
10 mM * 1 mL in DMSO USD 79 In-stock
Solid + Solvent
10 mM * 1 mL
ready for reconstitution
USD 79 In-stock
Solid
100 mg USD 72 In-stock
200 mg USD 102 In-stock
500 mg   Get quote  
1 g   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 67 publication(s) in Google Scholar

Other Forms of Docetaxel:

Top Publications Citing Use of Products

65 Publications Citing Use of MCE Docetaxel

WB

    Docetaxel purchased from MCE. Usage Cited in: Arch Biochem Biophys. 2023 Feb 21;109551.  [Abstract]

    Docetaxel (30 nM) exhibits anti-tumor activity in parental (DU145 and PC-3) and docetaxel-resistant (DU145/DTX50 and PC-3/DTX30) cell lines by down-regulating KIF14 expression.

    Docetaxel purchased from MCE. Usage Cited in: Oncotarget. 2016 May 17;7(20):28891-902.  [Abstract]

    Western blot analyses for Brachyury and AR expression in prostate cell lines treated with Docetaxel (Doc) or with XRP6258 (Cab). Graphs represent the densimetric semi-quantification of western blot images.
    • Biological Activity

    • Protocol

    • Purity & Documentation

    • References

    • Customer Review

    Description

    Docetaxel (RP-56976) is a microtubule depolymerization inhibitor, with an IC50 of 0.2 μM. Docetaxel attenuates the effects of bcl-2 and bcl-xL gene expression. Docetaxel arrests the cell cycle at G2/M and leads to cell apoptosis. Docetaxel has anti-cancer activity[1][3].

    IC50 & Target

    Human Endogenous Metabolite

     

    In Vitro

    Docetaxel (RP-56976) and Glufosfamide (GLU) single and combined treatments affect the cells viability in a dose-dependent manner. The IC50 of GLU are 70±4 µM and 86.8±8 µM in PC-3 and LNCaP cells; respectively. While, the IC50 of Docetaxel alone is found to be 3.08±0.4 nM and 1.46±0.2 nM in PC-3 and LNCaP cells; respectively.
    The co-treatment of GLU with Docetaxel is found to synergize the cytotoxicity and the IC50 values are decreased to be 2.7±0.1 nM and 0.75±0.3 nM in PC-3 and LNCaP cells; respectively[1].
    IC50 of NCI-H460 to Docetaxel at 24 h is 116 nM and at 72 h is 30 nM. According to data reported in DTP Data Search, the mean IC50 of NCI-60 cell panel to Docetaxel is 14-34 nM[2].

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    In Vivo

    In female mice, the Docetaxel (RP-56976)-induced intestinal apoptosis in the 14-hours after light on (HALO) group is significantly greater than that in the 2-HALO group. Bax expression is significantly elevated by Docetaxel in the 2-HALO group, but not in the 14-HALO group. On the other hand, cleaved Caspase-3 expression is significantly elevated by Docetaxel in the 14-HALO group, but not in the 2-HALO group. The expressions of Wee1 and phosphorylated CKD1 are significantly elevated after dosing of Docetaxel at 14 HALO, but not at 2 HALO. In addition, Docetaxel significantly reduces survivin expression in the 14-HALO group but not in the 2-HALO group. The survivin expression level in the Docetaxel-treated 14-HALO group is significantly smaller than that in the drug-treated 2-HALO group[3].
    Piperine (PIP) is administrated via intravenous bolus at 3.5 mg/kg and via oral administration at 35 mg/kg and 3.5 mg/kg, while Docetaxel (DOX) is intravenously administrated at 7 mg/kg to Sprague-Daley rats. The co-administrations of PIP at 35 mg/kg via oral administration and Docetaxel at 7 mg/kg via intravenous bolus administration in Sprague-Dawley rats. The combination use of PIP and Docetaxel results in a synergic increase of both their in vivo exposure[4].

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    Clinical Trial
    Molecular Weight

    807.88

    Appearance

    Solid

    Formula

    C43H53NO14

    CAS No.
    SMILES

    O=C(OC(C)(C)C)N[[email protected]@H](C1=CC=CC=C1)[[email protected]](C(O[[email protected]@H]2C(C)=C([[email protected]@H](O)C([[email protected]@]3(C)[[email protected]]([[email protected]@](CO4)(OC(C)=O)[[email protected]@]4([H])C[[email protected]@H]3O)([H])[[email protected]@H]5OC(C6=CC=CC=C6)=O)=O)C(C)(C)[[email protected]@]5(O)C2)=O)O

    Shipping

    Room temperature in continental US; may vary elsewhere.

    Storage

    4°C, protect from light

    *In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

    Solvent & Solubility
    In Vitro: 

    DMSO : 100 mg/mL (123.78 mM; Need ultrasonic)

    Ethanol : 50 mg/mL (61.89 mM; Need ultrasonic)

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 1.2378 mL 6.1890 mL 12.3781 mL
    5 mM 0.2476 mL 1.2378 mL 2.4756 mL
    10 mM 0.1238 mL 0.6189 mL 1.2378 mL
    *Please refer to the solubility information to select the appropriate solvent.
    In Vivo:
    • 1.

      Add each solvent one by one:  10% EtOH    40% PEG300    5% Tween-80    45% saline

      Solubility: ≥ 5 mg/mL (6.19 mM); Clear solution

    • 2.

      Add each solvent one by one:  10% EtOH    90% corn oil

      Solubility: ≥ 5 mg/mL (6.19 mM); Clear solution

    • 3.

      Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% saline

      Solubility: ≥ 2.08 mg/mL (2.57 mM); Clear solution

    • 4.

      Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% saline

      Solubility: ≥ 2.08 mg/mL (2.57 mM); Clear solution

    • 5.

      Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% saline

      Solubility: ≥ 2.08 mg/mL (2.57 mM); Clear solution

    • 6.

      Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% saline

      Solubility: ≥ 2.08 mg/mL (2.57 mM); Clear solution

    • 7.

      Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in saline)

      Solubility: ≥ 2.08 mg/mL (2.57 mM); Clear solution

    • 8.

      Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in saline)

      Solubility: ≥ 2.08 mg/mL (2.57 mM); Clear solution

    • 9.

      Add each solvent one by one:  10% DMSO    90% corn oil

      Solubility: ≥ 2.08 mg/mL (2.57 mM); Clear solution

    • 10.

      Add each solvent one by one:  10% DMSO    90% corn oil

      Solubility: ≥ 2.08 mg/mL (2.57 mM); Clear solution

    • 11.

      Add each solvent one by one:  10% DMSO    90% corn oil

      Solubility: ≥ 2.08 mg/mL (2.57 mM); Clear solution

    • 12.

      Add each solvent one by one:  10% DMSO    90% corn oil

      Solubility: ≥ 2.08 mg/mL (2.57 mM); Clear solution

    *All of the co-solvents are available by MCE.
    Purity & Documentation

    Purity: 99.96%

    References
    Cell Assay
    [1]

    Single-drug concentration-response curves are assessed. Seeding is done at a density of 2,000 cells/well for PC-3 and LNCaP, in 96-well plates. Cells are treated with each single drug and their combination for 72 h at different drug concentrations. Docetaxel is used at concentrations of 0.1-1,000 nM. GLU is used at concentrations of 0.1-300 µm. Cytotoxicity is assessed at the end of drug exposure using SRB assay. Following 72 h exposure the cells are fixed with 10% trichloroacetic acid (150 µL) for 1 h at 4°C. Then, cells are stained for 10 min at room temperature with 0.4% SRB dissolved in 1% acetic acid. The plates are then air dried for 24 h and the dye is made soluble with 150 µL Tris (10 mM, PH 7.4) for 5 min on a shaker at 1,600 rpm. Absorbance is then measured at 545 nM using microplate reader. Results are expressed as the relative percentage of absorbance compared to control[1].

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Administration
    [3][4]

    Mice[3]
    Five-week-old male Balb/c mice are used. Docetaxel (0, 10, 20, 30, 40, 60, and 80 mg/kg per week) is given once a week for 3 weeks for mice. Because more than 30 mg/kg per week of Docetaxel causes body weight loss in mice, 20 mg/kg per week of Docetaxel is judged to be the maximum nontoxic dose. Docetaxel (20 mg/kg per week) is given to mice once a week for 3 weeks at one of the following different points (2, 10, 14, or 22 HALO). Seventy-two hours after the final dosing of the agent, the intestinal mucosa of the small intestine (proximal 8 cm) is removed, fixed in 20 N Mildform solution (containing 8% formaldehyde in a buffered solution), and embedded in paraffin blocks, and sections of 5 μm are put on glass slides. Apoptosis is detected using the terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) method, using the Apop Tag Peroxidase In Situ Apoptosis Detection Kit.
    Rats[4]
    Male Sprague-Dawley rats with body weight between 230-250 g and age between 6-7 weeks are used. About 25 SD rats are divided into five groups receiving Docetaxel (7 mg/kg, i.v.), PIP (35 mg/kg, p.o.) and their combined administration (DOX+PIP) as well as PIP (3.5 mg/kg, p.o.) and PIP (3.5 mg/kg, i.v.). A day before the drug administrations, the rats are anesthetized. Right jugular vein is cannulated with a polyethylene tubing (0.5 mm ID, 1 mm) for blood collection.

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    References
    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.
    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    • Molarity Calculator

    • Dilution Calculator

    The molarity calculator equation

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass   Concentration   Volume   Molecular Weight *
    = × ×

    The dilution calculator equation

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
    × = ×
    C1   V1   C2   V2

    Your Recently Viewed Products:

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product Name

     

    Salutation

    Applicant Name *

     

    Email address *

    Phone number *

     

    Organization name *

    Department *

     

    Requested quantity *

    Country or Region *

         

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    Docetaxel
    Cat. No.:
    HY-B0011
    Quantity:
    MCE Japan Authorized Agent: